Monitoring and improving treatment for non-Hodgkin lymphoma patients in the Czech Republic
The Incidence, Epidemiology, Clinical Characteristic, Prognostic Factors, Therapy and Outcome of Non-Hodgkin Lymphoma Patients in the Czech Republic. NiHiL- Longitudinal Observational Study of Czech Lymphoma Study Group (CLSG)
This study is trying to gather and analyze information about non-Hodgkin lymphoma patients in the Czech Republic to improve their diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Czech Lymphoma Study Group Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Prague) |
| Trial ID | NCT03199066 on ClinicalTrials.gov |
What this trial studies
The Czech National Lymphoma Registry (NiHiL) aims to collect and analyze epidemiological data to enhance the diagnostic evaluation and treatment quality for patients with non-Hodgkin lymphoma (NHL). Patients are registered anonymously at diagnosis, and their data is updated throughout treatment and follow-up. The registry includes comprehensive information on lymphoma subtypes, treatment responses, and long-term outcomes, allowing for detailed analysis of survival rates and treatment efficacy. This initiative encompasses approximately 75% of NHL patients in the Czech Republic, providing a robust dataset for improving patient care.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with non-Hodgkin lymphoma who are treated in the Czech Republic and can provide informed consent.
Not a fit: Patients under 18 years of age or those who do not provide signed informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment strategies and outcomes for patients with non-Hodgkin lymphoma.
How similar studies have performed: Other observational studies have shown success in improving treatment outcomes through comprehensive data collection, making this approach both validated and essential.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * lymphoma diagnosis * treated in the Czech Republic * signed informed consent Exclusion Criteria: * unsigned informed consent * age \<18 y
Where this trial is running
Prague
- Charles University General Hospital — Prague, Czechia (Recruiting)
Study contacts
- Principal investigator: Marek Trneny, prof. MD — Charles University General Hospital, Prague, CZ
- Study coordinator: Marek Trneny, prof. MD
- Email: trneny@cesnet.cz
- Phone: +420224962061
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.